Viking Therapeutics (VKTX) Misses Q4 EPS by 12c

Viking Therapeutics (NASDAQ: VKTX) reported Q4 EPS of ($0.56), $0.12 worse than the analyst estimate of ($0.44). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Viking Therapeutics (VKTX) click here.

You May Also Be Interested In

• Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
• Cracker Barrel (CBRL) Tops Q4 EPS by 89c, Offers Guidance
• Worthington Industries (WOR) Tops Q1 EPS by 7c